Stereotaxis Q3 2026 earnings
Revenue growth accelerates to 20% YoY and 16% QoQ, but gross margin compresses to 45% and adjusted net loss widens to ($5.2)M due to acquisition integration costs.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $8.9M | +20% | +16% | Ex. 99.1, income statement |
| EPS (GAAP) | -$0.07 | 0.0 pp | 0.0 pp | Ex. 99.1, income statement |
| EPS (adjusted) | -$0.07 | +0.0 pp | 0.0 pp | Ex. 99.1, income statement |
| Net income | -$6.5M | +0.0 pp | +0.0 pp | Ex. 99.1, income statement |
| Adj. EBITDA | -$2.0M | +0.0 pp | 0.0 pp | Ex. 99.1, income statement |
| Adj. EBITDA margin | -22.5% | +0.0 pp | -1.2 pp | Ex. 99.1, income statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Systems | $3.0M | +61% | 34% | Partial revenue recognition from first GenesisX in US, first Genesis in China, and first full quarter of Synchrony sales |
| Disposables, service and accessories | $5.9M | +6% | 66% | Robotically-navigated catheter contributions offset by procedural pressure from supply shortages |
Margins and costs
- Gross margin 45% (prior 58%, change -13.0 pp)
- Operating expenses $10.4M (+22% YoY)
- One-offs in the quarter $1.3M non-cash charges (stock comp, mark-to-market, amortization); $2.0M acquisition transaction costs; $3.9M payments associated with Robocath acquisition
- Effective tax rate 5% (prior-year 5%, year-to-date 5%)
- Non-GAAP bridge Adds back stock compensation, mark-to-market adjustment for contingent earnout, and amortization of acquired intangible assets.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash and cash equivalents | $4.0M | $10.5M | $3.9M | -$6.5M |
| Pro forma cash balance | $16M | N/A | N/A | N/A |
| Backlog | $1.9M | N/A | N/A | N/A |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Adjusted operating expenses | Approximately $8M per quarter | Consistent with prior quarter | N/A |
| Cash flow profitability | Within the next year | First half of 2027 | Accelerated |
What drove it
- Revenue story Total revenue increased 20% YoY and 16% QoQ to $8.9M. Systems revenue surged 61% YoY to $3.0M, driven by the first GenesisX system in the US, first Genesis system in China, and full quarter of Synchrony sales. Recurring revenue increased 6% YoY to $5.9M, supported by new robotically-navigated catheters, but declined 4% QoQ due to supply constraints.
- EPS story Adjusted net loss widened to ($5.2)M, driven by one-time acquisition transaction costs and the absorption of Robocath operating expense.
- One-off check $1.3M non-cash charges (stock comp, mark-to-market, amortization) and $2.0M acquisition transaction costs.
The good
- Systems revenue up 61% YoY
- Backlog of $1.9M in disposable orders
- Convertible note financing provides $28M total availability
The bad
- Recurring revenue down 4% QoQ due to supply constraints
- Adjusted operating expenses increasing due to integration costs
The ugly
- Gross margin compressed to 45% due to fixed overhead allocated over low production volume
Open questions
- When will supply constraints with MAGiC be resolved?
- What are the specific regulatory milestones required to draw the additional $12M under the convertible note financing?
Full release
Stereotaxis (STXS) earnings release, November 10, 2026
Exhibit
99.1
Stereotaxis
Reports 2026 Third Quarter Financial Results & Business Updates
St.
Louis, November 10, 2026 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the third quarter ended September 30, 2026.
“Our near-term priority is to drive forward two major business model transformations,” said David Fischel, Chairman and CEO. “The first is shifting from capital systems that require long sales and construction timelines, to having a portfolio of systems that are significantly more accessible and scalable. The second is developing and commercializing a portfolio of disposable interventional catheters that enhance the value of our robots and provide a robust recurring revenue opportunity.”
“System revenue of $3 million in the quarter was up 60% compared to last year, benefiting from partial revenue recognition from the first GenesisX system in the US, the first Genesis system in China, and multiple Synchrony digital operating room systems in the US. Recurring revenue increased 6% over the previous year with a significant increase in revenue from our new portfolio of robotically-navigated catheters, countered by general pressure on procedures due to supply shortages. We entered the fourth quarter with a backlog of approximately $1.9 million in disposable orders we did not convert to revenue because of supply constraints.”
“In parallel to our commercial efforts, we continue to invest in a broad pipeline of innovations that expand our technology into a platform across endovascular surgery, enhance our competitiveness in electrophysiology, and deliver digital connectivity, automation and intelligence to the operating room. We were pleased during the past quarter to close the acquisition of Robocath and announce a collaboration with
Canon.”
2026
Third Quarter Financial Results
Revenue for the third quarter of 2026 totaled $8.9 million, a 20% increase compared to $7.5 million in the prior year third quarter and a 16% increase sequentially compared to $7.7 million in the second quarter of 2026. System revenue of $3.0 million increased from $1.9 million in the prior year third quarter. System revenue benefited from partial revenue recognition on the shipment of the first GenesisX system sold in the United States, the first Genesis system sold in China, and the first full quarter of Synchrony system sales. Recurring revenue of $5.9 million increased 6% compared to the prior year third quarter and declined 4% sequentially. Recurring revenue reflects increasing contributions from Stereotaxis’ portfolio of robotically-navigated catheters countered by general procedural pressure due to limited catheter supply.
Gross margin for the third quarter was 45% of revenue. Recurring revenue gross margin was 59%, and system gross margin was 15%. Gross margins for both recurring and system revenue remain impacted by fixed overhead allocated over low production volume. Operating expenses in the third quarter of $10.4 million included $1.3 million in non-cash charges for stock compensation expense, mark-to-market adjustment for acquisition related contingent earnout consideration, and amortization of acquired intangible assets. Excluding these non-cash charges, adjusted operating expenses were $9.1 million, an increase from $6.6 million in the prior year third quarter due to one-time acquisition transaction costs and the absorption of Robocath operating expense.
Operating loss and net loss in the third quarter of 2026 were ($6.5) million, compared with ($6.6) million and ($6.5) million, respectively, in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash charges, were ($5.1) million and
($5.2) million, respectively, compared with ($2.5) million and ($2.4) million in the previous year, with the increase predominantly driven by one-time transaction costs and the absorption of Robocath operating expense. Negative cash flow for the third quarter was ($6.5) million, of which ($2.6) million was associated with the core Stereotaxis business and ($3.9) million were payments associated with the acquisition of Robocath.
Cash
Balance and Liquidity
At
September 30, 2026, Stereotaxis had cash and cash equivalents of $4.0 million. Concurrent with these financial results, Stereotaxis announced a convertible note financing of up to $24 million, with an initial upfront closing of $12 million and an additional $12 million draw available at Stereotaxis’ option following certain regulatory milestones. Incorporating the proceeds from this financing, Stereotaxis’ pro forma cash balance would be $16 million, with access to an additional $12 million providing for total availability of $28 million.
Forward
Looking Expectations
Stereotaxis expects growing recurring revenue and more consistent capital sales in the coming quarters. Near-term milestones that support these growth expectations include installing the first commercial GenesisX systems and resolving the supply constraints with MAGiC.
Adjusted operating expenses, excluding non-cash and one-time items, are expected to approximate $8 million per quarter going forward. Growth in revenue combined with stable operating expenses provide a pathway to cash-flow profitability within the next year.
Conference
Call and Webcast
Stereotaxis will host a conference call and webcast today, November 10, 2026, at 4:30 p.m. Eastern Time. To access the conference call, dial 800-715-9871
(US and Canada) or 646-307-1963 (International) and give the participant pass code 2568629. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.
About
Stereotaxis
Stereotaxis... (truncated)botics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory.
These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”,
Financial statements
Income Statement
Three Months Ended September 30, — (Unaudited) (in thousands, except share and per share amounts)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| Revenue: | ||||
| Systems | 2,976 | 1,861 | 5,774 | 6,863 |
| Disposables, service and accessories | 5,949 | 5,603 | 17,112 | 16,872 |
| Total revenue | 8,925 | 7,464 | 22,886 | 23,735 |
| Cost of revenue: | ||||
| Systems | 2,524 | 1,510 | 4,384 | 5,543 |
| Disposables, service and accessories | 2,445 | 1,853 | 6,265 | 5,448 |
| Total cost of revenue | 4,969 | 3,363 | 10,649 | 10,991 |
| Gross margin | 3,956 | 4,101 | 12,237 | 12,744 |
| Operating expenses: | ||||
| Research and development | 3,523 | 2,546 | 8,310 | 6,673 |
| Sales and marketing | 2,856 | 2,934 | 8,068 | 9,351 |
| General and administrative | 4,048 | 5,178 | 12,879 | 13,675 |
| Other | -492 | |||
| Total operating expenses | 10,427 | 10,658 | 29,257 | 29,207 |
| Operating loss | -6,471 | -6,557 | -17,020 | -16,463 |
| Other income | 3 | -5 | 2 | |
| Interest expense | -44 | -44 | ||
| Interest income | 33 | 91 | 258 | 349 |
| Net loss | -6,482 | -6,463 | -16,811 | -16,112 |
| Cumulative dividend on convertible preferred stock | -316 | -322 | -941 | -953 |
| Net loss attributable to common stockholders | -6,798 | -6,785 | -17,752 | -17,065 |
| Net loss per share attributed to common stockholders: | ||||
| Basic | -0.07 | -0.07 | -0.18 | -0.19 |
| Diluted | -0.07 | -0.07 | -0.18 | -0.19 |
| Weighted average number of common shares and equivalents: | ||||
| Basic | 102,547,843 | 92,013,791 | 100,525,085 | 89,260,628 |
| Diluted | 102,547,843 | 92,013,791 | 100,525,085 | 89,260,628 |
Balance Sheet
September 30, 2026 — CONSOLIDATED BALANCE SHEETS (in thousands, except share amounts)
| September 30, 2026 – (Unaudited) | December 31, 2025 | |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | 3,976 | 13,421 |
| Accounts receivable, net of allowance of $808 and $541 at 2026 and 2025, respectively | 5,585 | 5,847 |
| Insurance receivable | 9,982 | 4,316 |
| Inventories, net | 13,272 | 9,567 |
| Prepaid expenses and other current assets | 1,628 | 698 |
| Total current assets | 34,443 | 33,849 |
| Investment in affiliate | 1,701 | |
| Property and equipment, net | 4,116 | 3,019 |
| Goodwill | 29,276 | 3,764 |
| Intangible assets, net | 6,988 | 6,429 |
| Operating lease right-of-use assets | 4,931 | 4,912 |
| Prepaid and other non-current assets | 657 | 278 |
| Total assets | 82,112 | 52,251 |
| Current liabilities: | ||
| Accounts payable | 7,718 | 4,768 |
| Accrued liabilities | 2,419 | 2,065 |
| Accrued legal liabilities | 9,982 | 4,316 |
| Current portion of long-term debt | 548 | |
| Deferred revenue | 5,423 | 5,675 |
| Current contingent consideration | 4,854 | 4,894 |
| Current portion of operating lease liabilities | 816 | 642 |
| Total current liabilities | 31,760 | 22,360 |
| Long-term debt | 1,922 | |
| Long-term deferred revenue | 406 | 555 |
| Long-term contingent consideration | 14,928 | 4,724 |
| Operating lease liabilities | 4,624 | 4,794 |
| Other liabilities | 1,941 | 1,097 |
| Total liabilities | 55,581 | 33,530 |
| Series A - Convertible preferred stock: | ||
| Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized, 20,733 and 21,008 shares outstanding at 2026 and 2025, respectively | 5,171 | 5,240 |
| Stockholders’ equity: | ||
| Common stock, par value $0.001; 300,000,000 shares authorized, 100,833,120 and 95,339,628 shares issued at 2026 and 2025, respectively | 101 | 95 |
| Additional paid-in capital | 621,818 | 596,960 |
| Treasury stock, 4,015 shares at 2026 and 2025 | -206 | -206 |
| Accumulated deficit | -600,179 | -583,368 |
| Accumulated other comprehensive income (loss) | -174 | |
| Total stockholders’ equity | 21,360 | 13,481 |
| Total liabilities and stockholders’ equity | 82,112 | 52,251 |
“estimate”, “project”, “expect” or similar expressions. These forward-looking statements include without limitation statements regarding the recently completed acquisition of Robocath, including the Company’s ability to advance its strategy, integrate Robocath, and grow revenue significantly without having to subject investors to substantial dilution; the completion of the Company’s offering convertible note financing; the ability to draw additional funds under the convertible note financing following receipt of required regulatory approvals; and the anticipated use of proceeds therefrom, usually containing the words “believe”,
“estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involving the following: the Company’s ability to manage expenses at sustainable levels; acceptance of the Company’s products in the marketplace; the effect of global economic conditions, including tariffs, on the ability and willingness of customers to purchase its technology; competitive factors; changes resulting from healthcare policy; dependence upon third-party vendors; timing of regulatory approvals, including as it relates to Robocath’s products and our ability to make further draws on the convertible note financing; the impact of pandemics or other disasters; statements generally relating to our recent acquisition of Robocath or our recently announced convertible note financing, including any benefits expected from either of those transactions, as well as any plans, forecasts and other expectations with respect to Robocath’s business following the completion of the transaction; and the other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission.
By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Additional information will also be set forth in future filings that we make with the SEC from time to time.
All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control and may be revised, modified, delayed, or canceled.
Company
Contacts:
David
L. Fischel
Chairman and Chief Executive Officer
Kimberly
R. Peery
Chief
Financial Officer
314-678-6100
Investors@Stereotaxis.com
Stereotaxis,
Inc.